A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment

Mise à jour : Il y a 4 ans
Référence : NCT01257178

Femme et Homme

Extrait

The purpose of this study is to evaluate the impact of hepatic dysfunction on the pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.


Critère d'inclusion

  • Insomnia

Liens